195 The Impact of Administration of Leukotriene Receptor Antagonists, Pranlukast-EK to Infants with Bronchial Asthma.

Background Bronchial asthma develops by the age of 3 years frequently in childhood in industrialized countries. Pranlukast hydrate, leukotriene receptor antagonists, has been shown to be clinically effective for the treatment of hypersensitivity and childhood asthma. The generic drugs for PLK were universally used in the market, and the effect of the drug also restrain the bronchial asthma onset of infants having an established allergic factor clinically, which necessitates the analysis of the mechanisms of allergic diseases and development of the effective treatment. Therefore we examined influence of administration of Pranlukast-EK (PLK-EK) on the symptom onset of a mild and moderate type of bronchial asthma.